RESUMO
BACKGROUND: Coronavirus disease 2019 (COVID-19) emerged as a public health crisis that disrupted normal patterns of health care in the New York City metropolitan area. In preparation for a large influx of critically ill patients, operating rooms (ORs) at NewYork-Presbyterian/Columbia University Irving Medical Center (NYP-Columbia) were converted into a novel intensive care unit (ICU) area, the operating room intensive care unit (ORICU). METHODS: Twenty-three ORs were converted into an 82-bed ORICU. Adaptations to the OR environment permitted the delivery of standard critical care therapies. Nonintensive-care-trained staff were educated on the basics of critical care and deployed in a hybrid staffing model. Anesthesia machines were repurposed as critical care ventilators, with accommodations to ensure reliable function and patient safety. To compare ORICU survivorship to outcomes in more traditional environments, we performed Kaplan-Meier survival analysis of all patients cared for in the ORICU, censoring data at the time of ORICU closure. We hypothesized that age, sex, and obesity may have influenced the risk of death. Thus, we estimated hazard ratios (HR) for death using Cox proportional hazard regression models with age, sex, and body mass index (BMI) as covariables and, separately, using older age (65 years and older) adjusted for sex and BMI. RESULTS: The ORICU cared for 133 patients from March 24 to May 14, 2020. Patients were transferred to the ORICU from other ICUs, inpatient wards, the emergency department, and other institutions. Patients remained in the ORICU until either transfer to another unit or death. As the hospital patient load decreased, patients were transferred out of the ORICU. This process was completed on May 14, 2020. At time of data censoring, 55 (41.4%) of patients had died. The estimated probability of survival 30 days after admission was 0.61 (95% confidence interval [CI], 0.52-0.69). Age was significantly associated with increased risk of mortality (HR = 1.05, 95% CI, 1.03-1.08, P < .001 for a 1-year increase in age). Patients who were ≥65 years were an estimated 3.17 times more likely to die than younger patients (95% CI, 1.78-5.63; P < .001) when adjusting for sex and BMI. CONCLUSIONS: A large number of critically ill COVID-19 patients were cared for in the ORICU, which substantially increased ICU capacity at NYP-Columbia. The estimated ORICU survival rate at 30 days was comparable to other reported rates, suggesting this was an effective approach to manage the influx of critically ill COVID-19 patients during a time of crisis.
Assuntos
COVID-19/mortalidade , COVID-19/terapia , Mortalidade Hospitalar , Hospitais Urbanos/organização & administração , Unidades de Terapia Intensiva/organização & administração , Salas Cirúrgicas/organização & administração , Idoso , COVID-19/diagnóstico , Estado Terminal/terapia , Feminino , Mortalidade Hospitalar/tendências , Hospitais Urbanos/tendências , Humanos , Unidades de Terapia Intensiva/tendências , Masculino , Pessoa de Meia-Idade , Cidade de Nova Iorque/epidemiologia , Salas Cirúrgicas/tendências , Organização e Administração , Taxa de Sobrevida/tendências , Resultado do TratamentoRESUMO
In this narrative review, anesthesiologists at 2 large hospital systems in New York City and San Francisco compare early coronavirus disease 2019 (COVID-19) public health outcomes while considering the role played by social vulnerability and relevant approaches in their 2 cities. An iterative search process allowed for a broad review of medical and public policy research, as well as newspaper reports, expert opinion, and multimedia sources, with the goal of exploring the importance of crowding, the labor force, and social identity in pandemic experiences. Related struggles, pitfalls, and successful interventions in both locales are summarized. Although technology in the form of vaccination will likely play an outsize role in the next phase of the pandemic, our review concludes that we must carefully consider how social vulnerabilities have and will continue to inform equitable and effective access to life-saving resources.
Assuntos
COVID-19 , Humanos , Cidade de Nova Iorque , SARS-CoV-2 , São Francisco , Vulnerabilidade SocialRESUMO
PURPOSE OF REVIEW: The development of hepatorenal syndrome in liver cirrhosis leads to an increased morbidity and mortality in patients with cirrhosis. Currently, there are no proven methods for the treatment or prevention of hepatorenal syndrome except to maintain adequate hemodynamics and intravascular volume in this patient population. These patients will frequently require renal replacement therapy when presenting for hepatic transplantation. RECENT FINDINGS: New consensus definitions have been published in order to create uniform standards for classifying and diagnosing acute kidney injury. Two such groups are the Acute Dialysis Quality Initiative (ADQI) and the Acute Kidney Injury Network (AKIN), which have proposed approaches to defining criteria for acute kidney injury. Recent literature supports not only the role of splanchnic vasodilation and systemic vasoconstriction but also heart failure in the pathogenesis of hepatorenal syndrome. The practice of using vasoconstrictor and intravenous albumin therapy for the treatment of hepatorenal syndrome is ongoing with a growing body of recent data supporting the use of vasopressin analogs as the first-line therapy in the ICU setting with knowledge of the possible cardiovascular side-effects. SUMMARY: Hepatorenal syndrome, HRS, is a diagnosis of exclusion. There are two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome. Type 1 HRS is rapidly progressive and portends a very poor prognosis and has a high mortality rate. Type 2 is more indolent while still associated with an overall poor prognosis. Treatment of HRS is largely still supportive. It is imperative to maintain euvolemia and hemodynamics in this patient population to optimize renal perfusion and preserve renal function. Renal replacement therapy may be necessary in this chronically ill patient population, if renal function deteriorates such that the kidneys cannot maintain metabolic and volume homeostasis. Further research is still necessary as to the prevention and effective treatment for hepatorenal syndrome.
Assuntos
Síndrome Hepatorrenal/complicações , Síndrome Hepatorrenal/prevenção & controle , Cirrose Hepática/complicações , Insuficiência Renal/complicações , Terapia de Substituição Renal/métodos , Injúria Renal Aguda/etiologia , Injúria Renal Aguda/terapia , Síndrome Hepatorrenal/classificação , Síndrome Hepatorrenal/diagnóstico , Síndrome Hepatorrenal/tratamento farmacológico , Síndrome Hepatorrenal/cirurgia , Humanos , Cirrose Hepática/cirurgia , Insuficiência Renal/etiologiaRESUMO
Hydatid disease (human echinococcosis) is a zoonotic infection caused by larval forms (metacestodes) of the genus Echinococcus. Although pulmonary hypertension (PH) due to hydatid disease has been described, it is quite rare. We report a patient with chronic echinococcal embolic PH in whom treatment with novel PH therapies permitted successful resection of the hepatic cyst with a good outcome.
Assuntos
Equinococose Pulmonar/complicações , Hipertensão Pulmonar/tratamento farmacológico , Hipertensão Pulmonar/etiologia , Embolia Pulmonar/complicações , Adulto , Anti-Hipertensivos/uso terapêutico , Bosentana , Doença Crônica , Equinococose Hepática/complicações , Equinococose Hepática/cirurgia , Epoprostenol/uso terapêutico , Hepatectomia , Humanos , Masculino , Artéria Pulmonar/parasitologia , Artéria Pulmonar/patologia , Sulfonamidas/uso terapêutico , Cirurgia Torácica Vídeoassistida , Veia Cava Inferior/cirurgiaRESUMO
Hepatic and renal disease are common comorbidities in patients presenting for intermediate- and high-risk surgery. With the evolution of perioperative medicine, anesthesiologists are encountering more patients who have significant hepatic and renal disease, both acute and chronic in nature. It is important that anesthesiologists have an in-depth understanding of the physiologic derangements seen with hepatic and renal disease to evaluate and manage these patients appropriately. Perioperative management requires an understanding of the physiologic perturbations associated with each disease process. This article elucidates the goals in the management and treatment of this complex patient population.
Assuntos
Anestesia/métodos , Nefropatias/complicações , Hepatopatias/complicações , Humanos , Nefropatias/fisiopatologia , Nefropatias/terapia , Hepatopatias/fisiopatologia , Hepatopatias/terapia , Cuidados Pré-Operatórios , AutocuidadoRESUMO
Patients who have undergone complete cavopulmonary anastomosis, the Fontan procedure, have passive venous blood flow from the superior and inferior vena cava into the pulmonary circulation without passing through the right ventricle. Although this procedure is an effective means of palliation, the resultant chronically increased central venous pressure, leads to several types of hepatic dysfunction including chronic congestion, cardiac cirrhosis, and even hepatocellular carcinoma. In this case report, we describe a patient with Fontan-associated hepatocellular carcinoma who successfully underwent a right hepatectomy.
RESUMO
Anesthesiologists often care for patients with renal insufficiency or renal failure. These patients may present to the operating room for a minor procedure such as an inguinal hernia repair or an arteriovenous fistula/graft. Alternatively, they may present for major abdominal operations or coronary artery bypass grafting. Critically ill patients presenting to the operating room may have acute kidney injury. It is imperative that the anesthesiologist understands the ramifications of renal failure and adjusts the anesthetic plan accordingly. Hemodynamic monitoring and fluid management can be challenging in this patient population. Various metabolic abnormalities can ensue that the anesthesiologist must be able to manage in the acute setting of the operating room.
Assuntos
Anestesia , Insuficiência Renal/complicações , Injúria Renal Aguda/complicações , Injúria Renal Aguda/epidemiologia , Anestesia/efeitos adversos , Cirurgia Geral , Humanos , Rim/fisiologia , Testes de Função Renal , Insuficiência Renal/tratamento farmacológico , Terapia de Substituição RenalRESUMO
The kidney is a remarkable organ whose functions include maintaining fluid and electrolyte balance, excreting metabolic waste products, and controlling vascular tone. Blood flow within the kidney is very heterogeneous, which places the metabolically active medulla at high risk for ischemic injury. A number of mediators play a role in the modulation of renal blood flow, including angiotensin II, dopamine, vasopressin, prostaglandins, atrial natriuretic peptide, endothelin, and nitric oxide. Early markers of renal injury elicit strong interest, although currently there is no reliable marker available. Surgery causes the release of catecholamines, renin, angiotensin, and AVP that lead to a redistribution of renal blood flow and a decrease in GFR. Additionally, general anesthesia often results in some degree of hypotension and depressed cardiac output, which further reduces renal perfusion and potentially jeopardizes renal function. A careful anesthetic plan is imperative in the patient with renal insufficiency or failure because acute renal failure in the perioperative period is associated with a high morbidity and mortality. Factors including advanced age, diabetes, underlying renal insufficiency, and heart failure place a patient at high risk for developing acute renal failure. It is imperative to maintain euvolemia, normotension, and cardiac output, and to avoid nephrotoxic agents to optimize renal blood flow and renal perfusion as the best prevention of renal dysfunction. Further studies are needed to establish if any therapies exist to prevent or treat renal dysfunction effectively.
Assuntos
Nefropatias , Circulação Renal/fisiologia , Anestésicos/farmacologia , Taxa de Filtração Glomerular/efeitos dos fármacos , Humanos , Rim/anatomia & histologia , Rim/efeitos dos fármacos , Nefropatias/complicações , Nefropatias/fisiopatologia , Circulação Renal/efeitos dos fármacos , Insuficiência Renal/tratamento farmacológicoRESUMO
Normal saline (NS; 0.9% NaCl) is administered during kidney transplantation to avoid the risk of hyperkalemia associated with potassium-containing fluids. Recent evidence suggests that NS may be associated with adverse effects that are not seen with balanced-salt fluids, e.g., lactated Ringer's solution (LR). We hypothesized that NS is detrimental to renal function in kidney transplant recipients. Adults undergoing kidney transplantation were enrolled in a prospective, randomized, double-blind clinical trial of NS versus LR for intraoperative IV fluid therapy. The primary outcome measure was creatinine concentration on postoperative Day 3. The study was terminated for safety reasons after interim analysis of data from 51 patients. Forty-eight patients underwent living donor kidney transplants, and three patients underwent cadaveric donor transplants. Twenty-six patients received NS, and 25 patients received LR. There was no difference between groups in the primary outcome measure. Five (19%) patients in the NS group versus zero (0%) patients in the LR group had potassium concentrations >6 mEq/L and were treated for hyperkalemia (P = 0.05). Eight (31%) patients in the NS group versus zero (0%) patients in the LR group were treated for metabolic acidosis (P = 0.004). NS did not adversely affect renal function. LR was associated with less hyperkalemia and acidosis compared with NS. LR may be a safe choice for IV fluid therapy in patients undergoing kidney transplantation.